Summary of Key Points
This year, pharmaceutical companies developing GLP-1 drugs (primarily used for weight loss and diabetes treatment) have begun to actively collaborate with insurance companies and e-commerce platforms due to limitations in traditional sales channels (failure to win bids in medical procurement auctions and intensified anti-corruption measures in the healthcare sector), as well as increased competition from domestic products. They have introduced commercial insurance products integrated into the medication purchase process (such as JD.com's "Shouyi Bao" and "Haoyao Bao") and are exploring the possibility of corporate group insurance programs. These partnerships not only help pharmaceutical companies expand their sales channels outside hospitals but also offer consumers discounts on medications. However, these products still fall short of mature Pharmaceutical Benefits Management (PBM) solutions, and the corporate group insurance market itself faces structural and policy challenges.
Why Are GLP-1 Drug Companies Suddenly Seeking Insurance Partnerships?
In the past, pharmaceutical companies sold GLP-1 drugs, which are used for chronic diseases, mainly through hospitals and medical insurance systems: the insurance would cover part of the cost, and doctors would prescribe the drugs, ensuring stable sales. However, things have changed in the past two years:
1. Narrowing Sales Channels: With the expansion of procurement auctions, companies that did not win bids had to sell their products through alternative channels such as pharmacies and e-commerce platforms. Additionally, stricter anti-corruption measures in healthcare have reduced frequent interactions between pharmaceutical companies and doctors, slowing down the conversion of prescriptions from hospitals to other sales channels.
2. Fierce Competition: By early 2026, there were six GLP-1 drugs approved for weight loss in China, four of which were domestic products (produced by companies like Innovent Biologics, Renhui Medicine, and Huadong Pharmaceutical), with more waiting to be approved. With so many competitors vying for the market, companies needed to find new sales channels.
3. E-commerce Platforms as a Valuable Asset: Platforms like JD.com and Taobao have large user bases, internet hospitals that can issue prescriptions, and delivery services, which make it convenient to integrate insurance solutions into the medication purchase process. For example, JD.com's Haoyao Bao has generated tens of millions in sales, representing more than 30% of the company's total GLP-1 drug sales.
Are GLP-1 Insurance Products on E-commerce Really Insurance or Just Price Discounts?
When purchasing GLP-1 drugs on JD.com, you might come across insurance options like Shouyi Bao, which charges a premium of 380 yuan and covers up to 1200 yuan in medication costs for half a year, with the discount applied directly during the purchase. Is this really insurance or just a discount?
1. It Looks Like a Discount, but It's Actually Insurance: Some might see this as a form of "scamming," but insurance companies calculate the risk based on probability. After all, not everyone who purchases the drug will use up the full 1200 yuan in coverage due to factors like side effects or stopping treatment after achieving weight loss. This is known as the "law of expectancy" in insurance.
2. Pharmaceutical Companies Play a Key Role: The success of these products relies on discounts offered by pharmaceutical companies to the platforms, such as negotiated supply prices and rebates. Insurance companies typically negotiate with third-party platforms (TPAs) to include these drugs in their product catalogs.
3. A Long Way from Mature PBM: While American PBM solutions manage not only insurance claims but also recommend cheaper alternative drugs and review the合理性 of prescriptions, current e-commerce insurance products only provide discounts, consultation services, and purchase assistance without addressing critical questions like "why this drug is needed" or "how much money can be saved with long-term use."
Can Corporate Group Insurance Accommodate GLP-1 Drugs?
In addition to e-commerce, pharmaceutical companies are also looking at corporate group insurance programs as a potential market. Is this feasible?
1. Advantages of Corporate Group Insurance: Corporate group insurance covers a stable population (tens or even hundreds of thousands of employees), allowing insurance companies to negotiate lower drug prices with pharmaceutical companies. It targets employees who are already insured, making it possible to identify those at risk of metabolic diseases (such as obesity and diabetes) more accurately.
2. Challenges of Corporate Group Insurance:
- Outdated Structures: Most group insurance premiums are currently used for minor outpatient expenses like colds and allergies, making it difficult for expensive chronic disease drugs to be included in the coverage.
- Budget Constraints: Companies are reluctant to increase their premium payments, and some insurance companies may experience net losses of 120%-130% due to competitive pricing.
- Policy Challenges: For example, Shanghai has implemented a fixed reimbursement policy for medical insurance since May, requiring patients to pay any amount exceeding the procurement auction price out of pocket. This adds additional pressure on group insurance programs to cover these costs.
3. Potential Benefits of Including GLP-1: Incorporating GLP-1 drugs into group insurance could be beneficial for long-term health management, as early use of these drugs can reduce future expenses related to diabetes and cardiovascular complications. However, pharmaceutical companies and insurance companies need to provide data demonstrating the value of these drugs, and companies must agree on who is eligible for coverage, the duration of coverage, and the amount of reimbursement.
The Impact of Insurance on GLP-1 Drugs
For pharmaceutical companies, insurance products represent a vital opportunity:
- New Sales Channels: They allow them to reach more patients by bypassing hospital restrictions through e-commerce and group insurance programs.
- Sales Growth: Insurance products on e-commerce platforms have already generated significant sales, and if corporate group insurance becomes popular, sales could increase even further.
- Brand Exposure: Since prescription drugs cannot be advertised on social media platforms like TikTok and REDnote, integrating insurance into the purchase process can help raise awareness of these drugs.
For consumers, insurance can provide cost savings. For example, Novo Nordisk's "Guai Ai Bao" offers a 40% discount on medication costs, directly reducing financial burdens.
For the entire industry, this development shifts the focus from post-illness reimbursement to proactive health management. By managing metabolic risks through GLP-1 drugs, insurance can help consumers save money in the long run. However, all of this is contingent on the products truly providing health benefits and on insurance companies and companies recognizing the long-term value of these solutions. Otherwise, these partnerships may remain short-lived.